EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSDNOG00000017521
Gene Symbol: PSMD1
2 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSDNOG00000011264
Gene Symbol: PSMD11
2 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSDNOG00000039420
Gene Symbol: PSMD12
2 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSDNOG00000012627
Gene Symbol: PSMD13
4 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSDNOG00000009794
Gene Symbol: PSMD14
2 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSDNOG00000009152
Gene Symbol: PSMD3
4 Cross references
94 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 4

Ensembl ID : ENSDNOG00000030681
Gene Symbol: PSMD4
3 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSDNOG00000046209
Gene Symbol: PSMD6
2 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSDNOG00000045847
Gene Symbol: PSMD7
4 Cross references
245 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSDNOG00000013547
Gene Symbol: PSMD8
2 Cross references
209 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSDNOG00000031139
Gene Symbol: LOC101426202
3 Cross references
238 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSDNOG00000048021
Gene Symbol: PSMB11
4 Cross references
228 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).